Mitotane increases the radiotherapy inhibitory effect and induces G 2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines

Endocrine-Related Cancer

Volumn 15, Issue 2, 2008, Pages 623-634

  Cerquetti, L ^a,b   Bucci, B ^b   Marchese, R ^b   Misiti, S ^a,b   De Paula, U ^b   Miceli, R ^b   Muleti, A ^b   Amendola, D ^b   Piergrossi, P ^b   Brunetti, E ^b   Toscano, V ^a   Stigliano, A ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B1; CYCLIN DEPENDENT KINASE 1; MITOTANE; PROTEIN P53;

ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL PROLIFERATION; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IONIZING RADIATION; RADIATION DOSE; RADIATION RESPONSE; SEQUENCE ANALYSIS; WESTERN BLOTTING; WILD TYPE;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; CDC2 PROTEIN KINASE; CELL DIVISION; CELL LINE, TUMOR; CYCLIN B; G2 PHASE; HUMANS; MITOTANE; RADIOTHERAPY; RNA, MESSENGER; STEROIDS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 45849101318     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.1315     Document Type: Article

References (43)

1. Allolio B & Fassnacht M 2006 Clinical review: adrenocortical carcinoma: clinical update. Journal of Clinical Endocrinology and Metabolism 91 2027-2037.
2. Beauregard C, Dickstein G & Lacroix A 2002 Classic and recent etiologist of Cushing's syndromes diagnosis and therapy. Treatments in Endocrinology 1 79-94.
3. Bodie B, Novick AC, Pontes JE, Straffon RA, Montie JE, Babiak T, Sheeler L & Schumacher P 1989 The Cleveland clinic experience with adrenal cortical carcinoma. Journal of Urology 141 257-260.
4. Butz J, Wickstrom E & Edwards J 2003 Characterization of mutations and loss of heterozygosity of p53 and K-ras2 in pancreatic cancer cell lines by immobilized polymerase chain reaction. BMC Biotechnology 23 3-11.
5. Calabria AR, Weidenfeller C, Jones AR, de Vries HE & Shusta EV 2006 Puromycin-purified rat brain microvascular endothelial cell cultures exhibit improved barrier properties in response to glucocorticoid induction. Journal of Neurochemistry 97 922-933.
6. Ceraline J, Deplanque G, Duclos B, Limacher JM, Vincent F, Goldblum S & Bergerat JP 1997 Relationship between p53 induction, cell cycle arrest and survival of normal human fibroblasts following DNA damage. Bulletin du Cancer 84 1007-1016.
7. Ciechanover A 1994 The ubiquitin-proteasome proteolytic pathway. Cell 79 13-21.
8. Concin N, Stimpfl M, Zeillinger C, Wolff U, Hefler L, Sedlak J, Leodolter S & Zeillinger R 2003 Role of p53 in G2/M cell cycle arrest and apoptosis in response to γ radiation in ovarian carcinoma cell lines. International Journal of Oncology 22 51-57.
9. De Crevoisier R, Baudin E, Bachelot A, Laboulleux S, Travagli JP, Caillou B & Schlumberger M 2004 Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. International Journal of Radiation Oncology, Biology, Physics 15 1137-1143.
10. Dan S & Yamori T 2001 Repression of cyclin B1 expression after treatment with adriamycin, but not cisplatin in human lung cancer A549 cells. Biochemical and Biophysical Research Communications 26 861-867.
11. Einhorn N, Lundell M, Nilsson B, Ragnarsson-Olding B & Sjovall K 1999 Is there place for radiotherapy in the treatment of advanced ovarian cancer? Radiotherapy and Oncology 53 213-218.
12. Hahner S & Fassnacht M 2005 Mitotane for adrenocortical carcinoma treatment. Current Opinion in Investigational Drugs 6 386-394.
13. Hochstrasser M 1996 Ubiquitin-dependent protein degradation. Annual Review of Genetics 30 405-439.
14. Hollstein M, Sidransky D, Vogelstein B & Harris CC 1991 p53 mutations in human cancers. Science 253 49-53.
15. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R & Harris CC 1994 Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Research 22 3551-3555.
16. Iliakis G, Wang YA, Guan J & Wang H 2003 DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene 22 5834-5847.
17. Jin P, Gu Y & Morgan DO 1996 Role of inhibitory CDC2 phosphorilation in radiation induced G2 arrest in human cells. Journal of Cell Biology 134 963-970.
18. Kao GD, McKenna WG & Yen TJ 2001 Detection of repair activity during the DNA damage, induced G2 arrest in human cancer cells. Oncogene 27 3486-3496.
19. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B & Craig RW 1991 Participation of p53 protein in the cellular response to DNA damage. Cancer Research 51 6304-6311.
20. Krause K, Wasner M, Reinhard W, Haugwitz U, Dohna CL, Mossner J & Engeland K 2000 The tumour suppressor protein p53 can suppress transcription of cyclin B. Nucleid Acids Research 28 4410-4418.
21. Di Leonardo A, Linke SP, Clarkin K & Wahl GM 1994 DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of CIP1 in normal human fibroblast. Genes and Development 8 2540-2551.
22. Marekova M, Cap J, Vokurkova D, Vavrova J & Cerman J 2003 Effect of therapeutic doses of ionising radiation on the somatomammotroph pituitary cell line, GH3. Endocrine Journal 50 621-628.
23. Markoe AM, Serber W, Micaily B & Brady LW 1991 Radiation therapy for adjunctive treatment of adrenalcortical carcinoma. American Journal of Clinical Oncology 14 170-174.
24. Minemoto Y, Uchida S, Ohtsubo M, Shimura M, Sasagawa T, Hirata M, Nakagama H, Ishizaka Y & Yamashita K 2003 Loss of p53 induces M-phase retardation following G2 DNA damage checkpoint abrogation. Archives of Biochemistry and Biophysics 412 13-19.
25. Morton G & Thomas GM 1994 Role of radiotherapy in the treatment of the cancer of the ovary. Seminars in Surgical Oncology 10 305-312.
26. Nader S, Hickey RC, Sellin RV & Samaan NA 1983 Adrenal cortical carcinoma. A study of 77 cases. Cancer 52 707-711.
27. Nome RV, Bratland A, Harman G, Fodstad O, Anderson Y & Ree AH 2005 Cell cycle checkpoint signalling involved in histone deacytalse inhibition and radiation induced cell death. Molecular Cancer Therapeutics 8 1231-1238.
28. Ohgaki H, Kleihues P & Heitz PU 1993 p53 mutations in sporadic adrenocortical tumors. International Journal of Cancer 54 408-410.
29. Percarpio B & Knowlton AH 1976 Radiation therapy of adrenal cortical carcinoma. Acta Radiological: Therapy, Physics, Biology 15 288-292.
30. Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin CM, Weir L, Gelmon K et al. 2005 Locoregional radiation therapy in patient with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. Journal of the National Cancer Institute 97 116-126.
31. Reed M, Woelker B, Wang P, Wang Y, Anderson ME & Tegtmeyer P 1995 The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. PNAS 92 9455-9459.
32. Reincke M, Karl M, Travis WH, Mastorakos G, Allolio B, Linehan HM & Chrousos GP 1994 p53 mutations in human adrenocortical neoplasm: immunohistochemical and molecular studies. Journal of Clinical Endocrinology and Metabolism 78 790-794.
33. Schteingart DE 1992 Treating adrenal cancer. Endocrinologist 2 149-157.
34. Schteingart DE, Sinsheimer JE, Counsell RE, Abrams GD, McClellan N, Djanegara T, Hines J, Ruangwises N, Benitez R & Wotring LL 1993 Comparison of the adrenalityc activity of mitotane and a methylated homolg on normal adrenal cortex and adrenal cortical carcinoma. Cancer Chemotherapy and Pharmacology 31 459-466.
35. Shimamura H, Sunamura M, Tsuchihara K, Egawa S, Takeda K & Matsuno S 2005 Irradiated pancreatic cancer cells undergo both apoptosis and necrosis, and could be phagocytized by dendritic cells. European Surgical Research 37 228-234.
36. Smeets MF, Mooren EH & Begg AC 1994 The effect of radiation on G2 blocks, cyclin B expression and cdc2 expression in human squamous carcinoma cell lines with different radiosensitivities. Radiotherapy and Oncology 33 217-227.
37. Van der Steene J, Soete G & Storme G 2000 Adjuvant radiotherapy for breast cancer significantly improves overall survival. Radiotherapy and Oncology 55 263-272.
38. Sudakin V, Ganoth D, Dahan A, Heller H, Hershko J, Luca FC, Ruderman JV & Hershko A 1995 The cyclosome a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis. Molecular Biology of the Cell 6 185-197.
39. Trainer P & Besser M 1994 Cushing's syndrome. Therapy directed at the adrenal glands. Endocrinology and Metabolism Clinics of North America 23 571-584.
40. Varshavsky A 1997 The ubiquitin system. Trends in Biochemical Sciences 22 383-387.
41. Venkatesh S, Hickey RC, Sellin RV, Fernandez JF & Samaan NA 1989 Adrenal cortical carcinoma. Cancer 64 765-769.
42. Yano T, Linechan M, Anglard P, Lerman MI, Daniel LN, Stein CA, Robertson CN, LaRocca R & Zbar B 1989 Genetic changes in human adrenocortical carcinoma. Journal of the National Cancer Institute 81 518-523.
43. Zotchev SB, Protopopova M & Selivanova G 2000 p53 C-terminal interaction with DNA ends and gaps has opposing effect on specific DNA binding by the core. Nucleic Acids Research 28 4005-4012.